• 제목/요약/키워드: Calcitonin

검색결과 172건 처리시간 0.024초

신증후군 환아에서 스테로이드에 의한 골다공증 치료에 $1{\alpha}-(OH)D_3$와 Pamidronate의 효과 (The Effects of $1{\alpha}-(OH)D_3$ and Pamidronate on Steroid Induced Osteoporosis (SIO) in Children with Nephrotic Syndrome (NS))

  • 김성도;전혜원;조병수
    • Childhood Kidney Diseases
    • /
    • 제6권2호
    • /
    • pp.209-217
    • /
    • 2002
  • 목적: 스테로이드 투여 요법은 소아기의 신증후군에 있어 표준적인 치료요법이 되어왔다. 그러나, 성장하는 소아에서 장기간 스테로이드 투여로 인한 골다공증은 심각한 합병증의 하나이다. 최근 골다공증의 예방과 치료에 calcium, calcitonin, parathyroid hormone, vitamin D, bisphosphonate 제재 등이 성인환자에서 사용되어지고 있으나 소아 신증후군 환아에서의 치료보고는 거의 없는 실정이다. 이에 저자들은 $1{\alpha}-(OH)D_3$와 Pamidronate의 치료효과를 보고자 골밀도 이중 에너지 흡수법을 이용하여 연구하였다. 대상 및 방법 :경희대학교 의과대학 부속병원 소아과에서 장기간 스테로이드 치료를 받았으며 이차적 골다공증이 생긴 60 명의 환아를 대상으로 하였다. 30명에겐 $1{\alpha}-(OH)D_3$를, 30명에겐 Pamidronate를 투여하였고, 혈청 단백질, 알부민, 요소질소, 크레아티닌, 칼슘, 인의 농도와 골밀도의 변화를 약제 투여전과 투여 6개월 후에 각각 측정하였다. 결과 및 결론 : 대상 환아의 평균 연령은 $1{\alpha}-(OH)D_3$ 와 Pamidronate 투여 집단에서 각각 평균 $6.9{\pm}3.3$$6.5{\pm}2.05$ 였고, 평균 스테로이드 투여 기간은 $28.8{\pm}1.8$$27.6{\pm}1.0$였다. 혈청 생화학 검사는 두 치료군 모두에서 치료 전과 후의 유의한 차이를 보이지 않았으나, 골밀도는 각각 치료전 $0.472{\pm}0.12$$0.457{\pm}0.10\;g/cm^2$에서 치료후 $0.533{\pm}0.12$$0.529{\pm}0.09\;g/cm^2$ 으로 의미있게 증가하였다. (P<0.05) $1{\alpha}-(OH)D_3$ 와 Pamidronate는 모두 장기간 스테로이드 치료를 요하는 소아 신증후군 환자에서 골다공증의 예방과 치료에 좋은 효과를 보여 주었다.

  • PDF

견관절부 외상후 발생된 Shoulder-Hand Syndrome (A Case of the Shoulder-Hand Syndrome Caused by a Crush Injury of the Shoulder)

  • 전재수;이성근;송후빈;김선종;박욱;김성열
    • The Korean Journal of Pain
    • /
    • 제2권2호
    • /
    • pp.155-166
    • /
    • 1989
  • Bonica defined, that reflex sympathetic dystrophy (RSD) may develop pain, vasomotor abnoramalities, delayed functional recovery, and dystrophic changes on an affected area without major neurologic injury following trauma, surgery or one of several diseased states. This 45 year old male patient had been crushed on his left shoulder by a heavily laden rear car, during his job street cleaning about 10 years ago (1978). At first the pain was localizea only to the site of injury, but with time, it spreaded from the shoulder to the elbow and hand, with swelling. X-ray studies in the local clinic, showed no bone abnormalities of the affected site. During about 10 years following the injury, the had recieved several types of treatments such as nonsteroidal analgesics, steroid injections into the glenoidal cavity (10 times), physical therapy, some oriental herb medicines, and acupuncture over a period of 1~3 months annually. His shoulder pain and it's joint dysfunction persisted with recurrent paroxysmal aggrevation because of being mismanaged or neglected for a sufficiently long period these fore permiting progression of the sympathetic imbalance. On July 14 1988 when he visited our clinic. He complained of burning, aching and had a hyperpathic response or hyperesthesia in touch from the shoulder girdle to the elbow and the hand. Also the skin of the affected area was pale, cold, and there was much sweating of the axilla and palm, but no edema. The shoulder girdle was unable to move due to joint pain with marked weakness. We confirmed skin temperatures $5^{\circ}C$ lower than those of the unaffected axilla, elbow and palm of his hand, and his nails were slightly ridged with lateral arching and some were brittle. On X-ray findings of both the shoulder AP & lateral view, the left humerus and joint area showed diffuse post-traumatic osteoporosis and fibrous ankylozing with an osteoarthritis-like appearance. For evaluating the RSD and it's relief of pain, the left cervical sympathetic ganglion was blocked by injecting 0.5% bupivacaine 5 ml with normal saline 5 ml (=SGB). After 15 minutes following the SGB, the clinical efficacy of the block by the patients subjective score of pain intensity (=PSSPI), showed a 50% reduction of his shoulder and arm pain, which was burning in quality, and a hyperpathic response against palpation by the examiner. The skin temperatures of the axilla and palm rose to $4{\sim}5^{\circ}C$ more than those before the SGB. He felt that his left face and upper extremity became warmer than before the SGB, and that he had reduced sweating on his axilla and his palm. Horner's sign was also observed on his face and eyes. But his deep shoulder joint pain was not improved. For the control of the remaining shoulder joint pain, after 45 minutes following the SGB, a somatic sensory block was performed by injecting 0.5% bupivacaine 6 ml mixed with salmon calcitonin, $Tridol^{(R)}$, $Polydyn^{(R)}$ and triamcinolone into the fossa of the acromioclavicular joint region. The clinical effect of the somatic block showed an 80% releif of the deep joint pain by the PSSPI of the joint motion. Both blocks, as the above mentioned, were repeated a total of 28 times respectively, during 6 months, except the steroid was used just 3 times from the start. For maintaining the relieved pain level whilst using both blocks, we prescribed a low dose of clonazepam, prazocin, $Etravil^{(R)}$, codeine, etodolac micronized and antacids over 6 months. The result of the treatments were as follows; 1) The burning, aching and hyperpathic condition which accompanied with vaosmotor and pseudomotor dysfunction, disappeared gradually to almost nothing, within 3 weeks from the starting of the blocks every other day. 2) The joint disability of the affected area was improved little by little within 6 months. 3) The post-traumatic osteoporosis, fibrous ankylosis and marginal sclerosis with a narrowed joint, showed not much improvement on the X-ray findings (on April 25, 1989) 10 months later in the follow-up. 4) Now he has returned to his job as a street cleaner.

  • PDF

RIA 검사별 희석실험을 통한 결과의 상한치 검증 (Verification of the upper limit of results through dilution tests for RIA test)

  • 이근의;최진주;이영지;유선희;이선호
    • 핵의학기술
    • /
    • 제26권1호
    • /
    • pp.42-46
    • /
    • 2022
  • 핵의학과 검체검사에서 시행되는 모든 정량 검사는 정확도와 정밀도를 고려하여 측정가능범위 및 임상보고 가능범위가 설정되어 있다. 측정가능범위를 벗어난 검체는 희석 실험을 시행하여 최종 검사 결과를 보고해야 한다. 그동안 희석을 진행하는 검체의 수가 많지 않았고, 검사 종목별 희석액이 시약 마다 달라 검사자가 실험 종목마다 적절한 희석배수를 정하여 결과를 보고하는 데 어려움이 있었다. 이에 따라 RIA 검사별 최대 희석배수의 설정 및 임상보고가능범위의 상한치 검증이 필요하다고 판단되었다. 본 연구에서는 KOLAS를 바탕으로 설정된 임상보고 가능범위의 상한치를 검증하였고 그에 따른 각 종목의 최대희석배수를 설정하였다. 서울아산병원에서 시행하고 있는 모든 RIA 검사 중 희석하는 30종의 검사종목을 대상으로 연구를 진행하였다. 2021년 3월부터 7월까지 총 4개월간의 자료를 종목별로 취합하여 분석하였다. 각 검체는 검사 항목별 Kit 내 기재된 희석방법에 따라 D.W, Kit 내 전용 Diluent 혹은 0 Standard로 희석하였으며 2배, 4배 및 10, 102, 103, 104 등의 계단희석을 진행한 검체를 대상으로 하였다. 실험 결과의 유효성을 확인할 수 있는 지표로 실측값을 기댓값으로 나눈 백분율을 사용하였다. 본 연구에서는 백분율 허용범위를 80~120%로 설정하였으며 이를 만족한 실험 결과를 연구의 표본이 되는 N값으로 설정하였다. 총 30종의 검사항목 중 백분율 허용범위에 속하는 N값의 수가 5개 이상인 종목은 19종목이었다. 희석배수의 검증 결과 104로 설정된 검사는 𝛼-fetoprotein, Thyroglobulin으로 2종목이며, 103으로 설정된 검사는 CA-125, CEA, 𝛽-hCG로 3종목, 102으로 설정된 검사는 Free PSA, PSA, CA15-3, SCC, Ferritin, PTH, Cortisol, Calcitonin, Aldosterone 으로 9종목이다. 10으로 설정된 검사는 𝛽2-Microglobulin, C-peptide, Testosterone 3종목이 있다. 남은 2종목인 Renin Activity와 Follicle Stimulation Hormone은 각각 2배, 4배로 설정하였다. 그 외 특이사항이 있는 항목은 11종목으로 허용범위를 벗어난 결과가 섞여 있어 표본이 부족하거나 희석검체 수가 부족하여 값을 설정하기 어려웠다. 이러한 종목들은 기존 자료를 토대로 희석배수를 설정하였고, 추후 자료를 수집하여 허용범위 내에 속하는 N값의 수가 충족된다면 희석배수를 재설정할 계획이다. 본 연구를 통해 임상보고 가능범위를 실증적 방식으로 검토하고, RIA 검사별 적절한 희석배수를 표준화함으로써 핵의학 검사의 경제성을 높이고, 연구를 통해 검증된 임상보고 가능범위 내에서 더욱 정확한 희석검사결과를 도출하는 데 도움이 되고자 하였다. 이를 통해 핵의학 혈액검사의 전반적인 질 향상을 기대해 볼 수 있으리라 사료된다.

진교의 파골세포 분화 및 골 흡수 유전자 억제기전 연구 (Gentianae Macrophyllae Radix Water Extract Inhibits RANKL-Induced Osteoclastogenesis and Osteoclast Specific Genes)

  • 양규진;김재현;김민선;류광현;문진호;이혜인;정혁상;손영주
    • Korean Journal of Acupuncture
    • /
    • 제37권2호
    • /
    • pp.63-75
    • /
    • 2020
  • Objectives : Osteoporosis is the most common bone disease and osteoporosis fracture is the leading cause of decreased life. Bisphosphonate and selective estrogen receptor modulators are the best choice of treatment for osteoporosis. However, when used for a long time, they increase the probability of side effect such as osteonecrosis of the jaw. Thus, it is crucial to develop alternative medicine to treat osteoporosis. Gentianae Macrophyllae Radix, a herbal medicine, is mainly to treat rheumatoid arthritis. However, the effect of the water extract of Gentianae Macrophyllae Radix (w-GM) on osteoporosis has not been investigated. Thus, we examine whether w-GM can inhibit osteoclast differentiation and bone resorption on receptor activator of nuclear factor kappa-B (NF-κB) ligand (RANKL)-treated RAW 264.7 cells. In this study, RAW 264.7 cells were used as an osteoclast differentiation model by treating them with RANKL. Methods : RAW 264.7 cells were used to determine the effect of w-GM on osteoclast differentiation and bone resorption. The number of tartrate-resistant acid phosphatase (TRAP)-positive cells, TRAP activity and pit formation assay were examined. In addition, protein expressions were measured by western blot and mRNA expressions were analyzed by reverse transcription polymerase chain reaction. Results : Treatment with w-GM inhibited the number of TRAP-positive cells, TRAP activity and pit area. In addition, w-GM decreased protein expression such as mitogen-activated protein kinase, NF-κB, c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1). It also inhibited the mRNA levels such as c-Fos, NFATc1, TRAP, NF-κB, calcitonin receptor and cathepsin K in RANKL-treated RAW 264.7 cells. Conclusions : These results suggest that w-GM has inhibitory effects via osteoclast differentiation, thus it could be a new medication for osteoporosis.

Dlx3 Plays a Role as a Positive Regulator of Osteoclast Differentiation

  • Cha, Ji-Hun;Ryoo, Hyun-Mo;Woo, Kyung-Mi;Kim, Gwan-Shik;Baek, Jeong-Hwa
    • International Journal of Oral Biology
    • /
    • 제32권3호
    • /
    • pp.85-91
    • /
    • 2007
  • Dlx3 is a homeodomain protein and is known to playa role in development and differentiation of many tissues. Deletion of four base pairs in DLX3 (NT3198) is causally related to tricho-dento-osseous (TDO) syndrome (OMIM # 190320), a genetic disorder manifested by taurodontism, hair abnormalities, and increased bone density in the cranium. Although the observed defects of TDO syndrome involves bone, little is known about the role of Dlx3 in bone remodeling process. In this study, we examined the effect of wild type DLX3 (wtDlx3) expression on osteoclast differentiation and compared it with that of 4-BP DEL DLX3 (TDO mtDlx3). To examine whether Dlx3 is expressed during RANKL-induced osteoclast differentiation, RAW264.7 cells were cultured in the presence of receptor activator of nuclear factor-B ligand (RANKL). Dlx3 protein level increased slightly after RANKL treatment for 1 day and peaked when the fusion of prefusion osteoclasts actively progressed. When wtDlx3 and TDO mtDlx3 were overexpressed in RAW264.7 cells, they enhanced RANKL-induced osteoclastogenesis and the expression of osteoclast differentiation marker genes such as calcitonin receptor, vitronectin receptor and cathepsin K. Since osteoclast differentiation is critically regulated by the balance between RANKL and osteoprotegerin (OPG), we examined the effect of Dlx3 overexpression on expression of RANKL and OPG in C2C12 cells in the presence of bone morphogenetic protein 2. Overexpression of wtDlx3 enhanced RANKL mRNA expression while slightly suppressed OPG expression. However, TDO mtDlx3 did not exert significant effects. This result suggests that inability of TDO mtDlx3 to regulate expression of RANKL and OPG may contribute to increased bone density in TDO syndrome patients. Taken together, it is suggested that Dlx3 playa role as a positive regulator of osteoclast differentiation via up-regulation of osteoclast differentiation-associated genes in osteoclasts, as well as via increasing the ratio of RANKL to OPG in osteoblastic cells.

Ca과 Vitamin D 보충이 폐경 이후 여성의 뼈대사에 미치는 영향 (The Effect of Ca and Vitamin D Supplementation on Bone Metabolism in Postmenopausal Women)

  • 홍희옥
    • Journal of Nutrition and Health
    • /
    • 제27권10호
    • /
    • pp.1025-1036
    • /
    • 1994
  • This study was designed to investigate the effects of Ca and/or vitamin D supplementation for 53 weeks on bone metabolism in postmenopausal women. The subjects were healthy 18 women aged from 59 to 69 years old. They were divided into three groups : placebo, Ca(1000mg/day) supplementation and Ca(1000mg/day) with vitamin D(12.5$\mu\textrm{g}$/day) supplementation. During the experimental periods except for metabolic studies, the subjects ate their usual diets and the use of drugs as well as excessive exercise was prohibited. Metabolic studies were conducted in the 1st week and in the 53rd week of the experimental periods. The subjects ate experimental diets which consisted of 1787.3kcal, 69.6g of protein, 561.5mg of Ca and 1078.6mg of P daily during both of the metabolic study periods. The results were summarized as follows; 1) Bone density of the second lumbar spine and trochanter measured after treatment decreased significantly in control group as compared with pre-experimental level(p<0.05). On the contrary, bone density of femoral neck and Ward's triangle in Ca group and the second lumbar spine in Ca.Vit D group increased significantly after treatment. 2) Serum PTH and calcitonin levels did not show any significant differences among groups before and after treatment. But serum PTH level increased significantly in all groups after treatment(P<0.05). 3) Serum Ca and P levels did not show any significant differences among groups before and after treatment. But serum Ca level increased significantly in all groups after treatment (P<0.05) and serum P level decreased significantly in Ca.Vit D group after treatment(P<0.05). 4) Mean 24-hours fecal Ca excretion of Ca group was the highest in the 1st week of treatment(P<0.01), and that of control group was the lowest in the 53rd week of treatment(P<0.01). Fecal Ca excretion increased significantly in control and Ca.Vit D group in the 53rd week of treatment(P<0.05). Urinary Ca excretion did not show any significant differences among groups in the 1st and 53rd week of treatment, but that of Ca.Vit D group was the highest the 1st week of treatment(P<0.01). In the 53rd week of treatment Ca and Ca.Vit D group showed positive Ca balance, but control group showed negative Ca balance. The above results showed that it will be difficult to prevent degenerative bone loss without Ca and/or vitamin D supplementation in postmenopausal women eating Korean usual diets.

  • PDF

이소플라본 보충과 운동의 병행이 성장기 쥐의 골격대사에 미치는 영향 (Effects of combined intervention of isoflavone supplementation and exercise on bone metabolism in growing rats)

  • 정윤정;최미자
    • Journal of Nutrition and Health
    • /
    • 제48권2호
    • /
    • pp.149-156
    • /
    • 2015
  • 이소플라본 보충과 운동의 병행이 성장기 암컷 흰쥐의 골격대사에 미치는 영향을 알아보고자 생화학적 골대사 지표 및 골대사 관련 호르몬, 척추와 대퇴 골밀도 및 골함량에 미치는 영향을 분석하였다. 그 결과, 체중증가량과 식이섭취량, 식이효율은 이소플라본 보충과 운동의 병행에 따라 실험군간에 유의적인 차이가 없었다. 골형성 지표인 혈중 ALP와 osteocalcin은 이소플라본 보충과 운동의 병행에 따라 실험군간에 유의적인 차이가 없었고, 골용해 지표인 요 중 DPD crosslink value는 실험군간에 유의적인 차이가 없었다. 골대사관련 호르몬인 혈중 부갑상선 호르몬, 칼시토닌 및 에스트로겐 농도도 실험군 간에 유의적인 차이가 없었다. 척추 골밀도, 척추 골함량 및 대퇴골함량은 이소플라본 보충과 운동의 병행에 의해 유의적인 차이가 없었고 대퇴골밀도는 IFR군이 대조군보다 유의적으로 높았다. 체중당 대퇴골함량은 IFS군이 대조군보다 유의적으로 높았다. 체중 당 척추골밀도 및 척추골함량, 체중 당 대퇴골밀도는 대조군과 비교하여 이소플라본 단독 보충, 달리기운동 병행, 수영운동 병행 모두 유의적으로 증가하여 실험군내에서 이소플라본 보충과 운동 병행에 따른 유의적 차이는 없었고 운동병행군에서는 운동형태에 따라 달리기와 수영 운동의 차이가 없었다. 결론적으로 성장기 쥐에서 이소플라본 보충과 운동의 병행은 이소플라본 단독보충과 비교하여 상승효과는 없었으나 이소플라본의 섭취 및 달리기와 수영운동 병행 각각은 척추 및 대퇴 골밀도와 골함량을 증가시켜 성장기 최대골밀도 형성에 유리한 것으로 나타났다.

어유의 n-3 지방산이 흰쥐의 골밀도와 골격대사지표에 미치는 영향 (Beneficial effect of fish oil on bone mineral density and biomarkers of bone metabolism in rats)

  • 윤군애
    • Journal of Nutrition and Health
    • /
    • 제45권2호
    • /
    • pp.121-126
    • /
    • 2012
  • 본 연구는 n-3 장쇄지방산이 풍부한 어유가 골격대사에 미치는 영향을 알아보고자 이유한 Sprague-Dawley 종 흰쥐 (수컷)에게 4주 동안 FO군, FICO군, SO군의 실험식이를 공급한 후, 혈액과 뇨에서 생화학적 골격대사지표와 대퇴골의 무기질함량 및 골밀도를 측정하였다. 부갑상선호르몬, 칼시토닌, 오스테오 칼신은 세 그룹 사이에 차이를 보이지 않았으며, 뼈흡수지표인 deoxypyridinoline도 그룹 간에 차이가 없는 것으로 나타났다. 반면에 골격형성지표인 ALP의 활성은 FO군에서 SO군에 비해 유의하게 높았고, 대퇴골의 골밀도 또한 SO군에 비해 FO군에서 유의하게 높은 값을 보였다. 그러나 FICO군과 SO군 간에는 차이가 없는 것으로 나타났다. 이러한 결과로 볼 때, 본 연구에서 DHA, EPA 급원의 어유 함량이 높은 식이는 ALP활성을 높이고 골밀도를 증대시킴으로써 성장기 흰쥐의 골격형성에 보호적인 효과가 있음을 알 수 있다. 그러나 식이 n-3 장쇄지방산이 골격대사에 미치는 효과를 규정하기 위해서는 적정식이수준이나 적정 n6/n3 비율과 관련된 많은 연구가 요구되며, n-3계 내의 각 지방산이 골격에 주는 작용양상에도 차이가 있을 수 있으므로 이에 대한 다양한 연구의 병행이 필요할 것으로 본다.

여성의 개인적 특성과 생활양식요인을 이용한 골량감소 예측모형 (Prediction Model for Reduced Bone mass in Women using Individual Characteristics & Life Style Factors)

  • 이은남;이은옥
    • 근관절건강학회지
    • /
    • 제5권1호
    • /
    • pp.83-109
    • /
    • 1998
  • This study was carried out to identify the Important modifiable risk factors for reduced bone mass and to construct prediction model which can classify women with either low or high bone mass. Through the literature review, individual characteristics such as age, body weight, height, education level, family history, age of menarche, postmenopausal period, gravity, parity, menopausal status, and breast feeding period were identified and factors of life style such as past milk consumption, past physical activity, present daily activity, present calcium intake, alcohol intake, cigarette smoking, coffee consumption were identified as influencing factors of reduced bone mass in women. Four hundred and eighty women aged between 28 and 76 who had given measurement bone mineral density by dual energy x-ray absortiometry in lumbar vertebrae and femur from July to October, 1997 at 4 general hospitals in Seoul and Pusan were selected for this study. Women were excluded if they had a history of any chronic illness such as rheumatoid arthritis, diabetes mellitus, hyperthroidism, & gastrointestinal disorder and any medication such as calcium supplements, calcitonin, estrogen, thyroxine, antacids, & corticosteroids known affect bone. As a result of these exclusion criteria, four hundred and seventeen women were used for analysis. Multiple logistic regression model was developed for estimating the likelihood of the presence or absence of reduced bone mass. A SAS procedure was used to estimate risk factor coefficient. The results are as follows For lumbar spine, the variables significant were age, body weight, menopause status, daily activity, past milk consumption, and past physical activity(p<0.01), while for femoral Ward's triangle, age, body weight, level of education, past milk consumption, past physical activity(p<0.001). Past physical activity, present daily activity and past milk consumption are the most powerful modifiable predictors in vertebrae and femur among the predictors. When the model performance was evaluated by comparing the observed outcome with predicted outcome, the model correctly identified 74.1% of persons with reduced bone mass and 84.5% of persons with normal bone mass in the lumbar vertebrae and 82.9% of persons with reduced bone mass and 75.0% of persons with normal bone mass in the femoral Ward's triangle. On the basis of these results, a number of recommendations for the management of reduced bone mass may be made : First, those woman who are classified as high risk group of the reduced bone mass in the prediction model should examine the bone mineral density to further examine the usefulness of this model. Second, the optimal amount of milk consumption and a regular weight bearing exercise in childhood, adolescence, and early adult should be ensured.

  • PDF

골다공증의 진단과 치료 (The Diagnosis and Treatment of Osteoporosis)

  • 문준성;원규장
    • Journal of Yeungnam Medical Science
    • /
    • 제25권1호
    • /
    • pp.19-30
    • /
    • 2008
  • 골다공증은 골밀도와 골의 질로 구성되는 골의 강도가 손상됨으로 골절의 위험이 높아지는 골격질환이며, 최근 유병율이 점차 증가하고 있는 추세이다. 임상적으로 무증상인 경우가 많으며 방사선학적 검사인 단순 방사선 검사, 골 스캔, CT, MRI 등이 골밀도 및 골절의 진단에 유용하다. 골밀도의 정량적 검사로는 이중에너지 방사선 흡수법, 정량적 전산화 단층촬영이 사용되고 있다. 골다공증의 진단은 WHO 기준에 따라 T-score가 -2.5 이하일 경우 진단할 수 있다. 그 외에 생화학적 골표지자들도 진단에 도움이 된다. 골다공증 치료제는 골흡수억제제와 골형성자극제(formation stimulator)로 나눌 수 있는데 골흡수억제제로는 칼슘, 에스트로겐, 칼시토닌, 비스포스포네이트(bisphosphonate), 비타민 D 등이 있으며 골량을 증가시키는 골형성자극제로는 현재 부갑상선 호르몬이 유일하며 최근 strontium ranelate가 추가되었다. 일일 1200 mg의 칼슘과 800 IU 의 비타민 D 섭취가 권장되고 있으며, 폐경기 여성에서 에스트로겐이 효과가 입증되었고 골다공증으로 인한 통증에는 칼시토닌이 효과가 있다. 비스포스포네이트는 폐경 후 골다공증의 치료, 예방 및 스테로이드에 의한 골다공증 치료에 대해 FDA의 승인을 받았다. 폐경 후 골다공증의 치료, 예방에 사용되는 SERM은 골의 질을 향상시킴으로써 골절을 예방한다고 알려져 있다. 골형성자극제인 부갑상선 호르몬이 골절의 위험을 감소시킨다고 보고된 바 있으며, strontium은 최근에 개발된 약제로 3상 연구에서 골절 위험율 감소효과를 보였으나 더 많은 연구가 필요할 것으로 생각된다.

  • PDF